1. Home
  2. CRDL vs INVZ Comparison

CRDL vs INVZ Comparison

Compare CRDL & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.18

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

Logo Innoviz Technologies Ltd. Ordinary shares

INVZ

Innoviz Technologies Ltd. Ordinary shares

HOLD

Current Price

$0.45

Market Cap

129.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDL
INVZ
Founded
2017
2016
Country
Canada
Israel
Employees
N/A
372
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
132.6M
129.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CRDL
INVZ
Price
$1.18
$0.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$8.50
$2.68
AVG Volume (30 Days)
806.5K
2.0M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.61
Revenue Next Year
N/A
$53.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.54
52 Week High
$1.71
$2.54

Technical Indicators

Market Signals
Indicator
CRDL
INVZ
Relative Strength Index (RSI) 53.46 31.22
Support Level $0.95 N/A
Resistance Level $1.38 $0.72
Average True Range (ATR) 0.10 0.04
MACD 0.01 -0.01
Stochastic Oscillator 60.13 14.04

Price Performance

Historical Comparison
CRDL
INVZ

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.

Share on Social Networks: